Buoyed by recent progress in its alliance with Sanofi SA, investors in the Danish diabetes drug developer Zealand Pharma A/S reacted calmly to news that another partner, Boehringer Ingelheim GmbH, was terminating its interest in ZP2929, a dual-acting agonist of the glucagon and glucagon-like peptide-1 (GLP-1) receptors.